Virta becoming GLP-1 off-ramp
Virta Health
This risk is really about Virta moving down the value chain, from selling a premium diabetes reversal program to being a utilization manager for expensive obesity drugs. Virta’s highest value product is still its diabetes reversal offering, which sells at about $2.8K per patient with outcome based fees and drives roughly $318K average revenue per customer, versus about $1K revenue per patient for Omada style maintenance programs and $900 per year for Virta’s obesity product. If employers increasingly buy Virta mainly to supervise, taper, or justify GLP-1 use, the product starts to look more like a required care management layer than a distinct first choice therapy.
-
Virta itself has leaned into this role. Its Responsible Prescribing program is explicitly positioned for employers, health plans, and PBMs as support with or without GLP-1s, including an off-ramp for medications. That helps sales today, but it also frames Virta as part of the drug management stack, not just the alternative to it.
-
The competitive set changes if that happens. Omada now offers GLP-1 Flex Care with clinical evaluation, prescribing, and ongoing oversight, and Evernorth has already embedded Omada in EncircleRx as the lifestyle support layer tied to GLP-1 coverage. In that world, Virta is competing less on reversal outcomes and more on who can manage drug spend for employers most efficiently.
-
Virta’s economics are strongest when it owns a differentiated workflow, connected glucose and ketone meters, frequent coach check ins, physician oversight, and insulin deprescribing for diabetes patients. Livongo and Omada historically monetize broader maintenance programs sold across large employer and health plan channels, which supports lower revenue per customer but much wider distribution.
Going forward, the winners in metabolic care will be the companies that can sit on both sides of the GLP-1 decision, helping employers approve the right patients, improve adherence, and safely step members down when drug costs get too high. Virta is well positioned if it keeps using off-ramp demand as an entry point into higher value reversal care, rather than letting that become the whole product.